ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: While TKI‐mediated BCR::ABL1 inhibition has revolutionised CML therapy, resistance remains a problem, and TKIs do not target the CML LSC population, requiring lifelong TKI therapy for the majority of patients.4